BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) has entered an agreement with Eurofins CDMO (contract development and manufacturing organization) Alphora Inc for the manufacturing of its LSD derivative molecule, TD-0148A, the company announced Wednesday.
TD-0148A is a second-generation lysergic acid diethylamide (LSD) derivative molecule, 2-bromo-LSD, that BetterLife believes will mimic the projected therapeutic potential of LSD, without causing its undesirable psychoactive dissociative side effects, such as hallucinations.
Eurofins CDMO will conduct process development, scale-up and GMP (good manufacturing practice) manufacturing of TD-0148A at its plant facility in Mississauga, Ontario. The manufacturing will be based on BetterLife’s proprietary process that does not involve any controlled substances, the company said.
READ: BetterLife Pharma files patent protection for its newest compound TD-010 to treat anxiolytic-use disorder
“Following our recent acquisition of Transcend Biodynamics, we are pleased to be moving rapidly ahead with the manufacturing program of TD-0148A for treatment of major depressive disorders and other indications,” BetterLife CEO Ahmad Doroudian said in a statement. “We look forward to working with Eurofins CDMO to bring this treatment to patients as quickly as possible as we prepare for our IND.”
BetterLife acquired Transcend for C$10 million in December, adding its LSD derivative BOL-148 to BetterLife’s drug pipeline.
“We are pleased to be partnering with Eurofins CDMO in the proprietary manufacturing of TD-0148A,” Doroudian said. “We believe our novel manufacturing process and product is a significant step forward in bringing non-hallucinogenic psychoactive drugs to patients in need. Eurofins CDMO with its state-of-the-art manufacturing plant and agile team is an ideal partner to help realize our vision.”
Earlier this year, BetterLife announced a partnership with Eurofins CDMO for pharmacology studies of TD-0148A.
“We are thrilled to be partnering with BetterLife to develop and manufacture their novel and transformative therapeutic for the treatment of various neuro-psychiatric disorders,” Eurofins CDMO Business Development Executive Stefan Soderman said. “Eurofins CDMO’s expertise, quality, and flexibility in process development, scale-up and cGMP manufacturing make us uniquely qualified to fulfill the contract development and manufacturing role for such an innovative product.”
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel